Viral pericarditis

Article written and reviewed by Dr Luca Moretti

The viral pericarditis is inflammation of the pericardium attributable to a viral infection, through local injury, an infection-associated immune response, or a combination of the two processes. In clinical practice the attribution is often presumptive: a pericarditic episode following a respiratory syndrome, in the absence of other recognizable causes, does not necessarily demonstrate the presence of the virus in the pericardium. It is therefore useful to distinguish documented viral disease from presumed viral pericarditis and from idiopathic pericarditis, even when the initial management of uncomplicated forms is similar.

Systemic infection, cardiac localization, and the mechanism that sustains inflammation do not necessarily coincide. A positive respiratory test may demonstrate a concomitant infection; a molecular signal in a cardiac sample requires interpretation in relation to latency, burden, localization, and sample characteristics. After the infection resolves, an immune response may also sustain pain and recurrences without active viral replication. These distinctions determine the meaning of testing and prevent every subsequent attack from being considered a new infection.

The most common presentation in immunocompetent clinical practice is an acute pericardial syndrome with a favorable prognosis, but myocardial involvement, immunosuppression, and severe systemic infections modify risk. The diagnosis should therefore describe both the degree of etiologic certainty and the extent of cardiac disease. A generic viral label is not sufficient to exclude tamponade, myocarditis, or alternative causes requiring specific treatment.

Viral agents, epidemiologic settings, and limits of attribution

Numerous viruses have been associated with pericardial disease, but the strength of the evidence and the types of populations studied are not uniform. Enteroviruses, including coxsackieviruses and echoviruses, are part of the traditional clinical spectrum of pericarditis and myopericarditis. Adenoviruses and influenza viruses may be implicated in cardiac presentations associated with respiratory infections. The list of possible agents, however, is not a reliable ranking of their frequency in outpatient pericarditis because many cases do not undergo direct causal investigation.

Among the DNA viruses, parvovirus B19 and several herpesviruses, including Epstein-Barr virus, cytomegalovirus, and human herpesvirus 6, have been described. Their detection raises specific problems: genome persistence, latency, and presence in circulating cells may make a positive result more difficult to interpret. The significance of the finding depends on the tissue or fluid analyzed, characteristics of the inflammation, and immune status. Simple identification of a viral sequence does not always amount to proof of replication responsible for injury.

In immunosuppression, reactivations and opportunistic infections become more relevant. Transplantation, chemotherapy, and immunosuppressive therapies modify both the pathogen spectrum and the clinical expression, sometimes attenuating fever and inflammatory response. Pericarditis in a person with HIV infection should not automatically be attributed to HIV itself: tuberculosis, other infections, malignancy, and noninfectious causes may explain the involvement. Etiologic definition therefore requires broader evaluation and often infectious disease coordination.

Infection with SARS-CoV-2 may be associated with isolated pericardial manifestations or myopericardial involvement, during the acute phase or subsequently. Temporal plausibility alone does not identify the mechanism: systemic response, inflammatory injury, and concomitant conditions may contribute. Chest pain and tachycardia after COVID-19 do not automatically demonstrate pericarditis because they may have different cardiovascular, pulmonary, or functional explanations. Evaluation must confirm the cardiac syndrome and its relevance, avoiding transfer of percentages obtained with different definitions or populations.

The seasonality and a preceding febrile syndrome may support an infectious hypothesis but lack sufficient specificity to identify the agent. The absence of prodromes likewise does not exclude a possible viral trigger. Apparent frequency depends on diagnostic methods and timing of sampling, as well as local epidemiology. Studies of biopsies and fluids from patients selected for severe disease cannot be used directly to estimate the incidence of each virus among mild cases that recover with conventional therapy.

The relationship with vaccinations and drugs should be described separately from infection. Pericarditis temporally associated with a vaccine is not thereby pericarditis caused by replication of the virus targeted by that vaccine. Similarly, reactivation during immunosuppression does not prove that the drug produced direct pericardial injury. Distinguishing exposure, mechanism, and available evidence avoids inappropriate categories and allows individualized therapeutic decisions without automatic causal attributions.

Infectious pathogenesis and postinfectious inflammation

Infection may reach the cardiac compartment during systemic dissemination, with tropism and behavior differing according to the agent and host. The interaction among pathogen, resident cells, and microcirculation activates danger signals and leukocyte recruitment. In truly infectious forms, direct injury may contribute to the immune response, but the relative weight of the two mechanisms cannot be inferred from the clinical picture alone. A painful presentation does not establish whether replication is still ongoing at the time of observation.

The innate immunity recognizes microbial structures and products of cell injury, generating cytokines and local amplification. The inflammasome and interleukin-1 participate in pericardial inflammatory pathways in relevant models and phenotypes but are not specific to any single virus. Their activation may continue after the trigger has diminished. This helps explain why anti-inflammatory therapy can control disease without direct antiviral action and why clinical efficacy does not demonstrate disappearance of an agent.

The adaptive response promotes control of infection and may at the same time contribute to tissue injury. In some patients the process becomes postinfectious or immune-mediated, with subsequent attacks not accompanied by evidence of replication. These models should not be turned into universal explanations: viral persistence has different meanings according to agent, compartment, and detection method. Knowledge derived from myocardial biopsies cannot automatically be transferred to the pericardium, and virus-positive myocarditis does not prove identical pericardial localization.

In inflamed tissue, increased vascular permeability produces edema and exudation; fibrin may deposit on the surfaces and fluid may increase in the cavity. The response may be predominantly dry and painful or effusive. These morphologic features depend on intensity, timing, and host response and do not identify the pathogen on their own. A hemorrhagic effusion, for example, also requires consideration of malignancy, trauma, and iatrogenic causes and should not be explained by a viral origin merely because a preceding viral illness occurred.

The resolution requires control of the trigger and downregulation of the response, with resorption of exudate and recovery of the surfaces. In favorable courses these processes occur without major structural damage. When inflammation persists, adhesions and remodeling may temporarily alter distensibility; permanent constrictive fibrosis remains rare in properly defined idiopathic or presumed viral categories. Marked progression should therefore prompt reconsideration of bacterial, tuberculous, neoplastic, and previous-injury causes.

The host predisposition influences severity and duration. Immune status, age, comorbidities, renal function, and concomitant therapies modify the balance between infection control and inflammatory injury. No single biomarker can separate active infection from a sterile phase in every patient. The most useful description therefore includes demonstrated or presumed agent, site of demonstration, inflammatory activity, and cardiac consequences. Such precision is essential before discussing antivirals or prolonged immunosuppression.

Pathophysiology and clinical manifestations

Irritation of the surfaces and adjacent structures produces chest pain, often worsened by inspiration, coughing, and the supine position. Improvement when sitting and leaning forward and radiation toward the trapezius are suggestive but not mandatory. Fever, myalgias, or respiratory symptoms may precede or accompany the episode. The temporal relationship helps formulate a hypothesis; without further evidence, it does not establish which virus is responsible or whether it is still present in the pericardium.

The dyspnea may result from pain limiting inspiration, the effusion, myocardial involvement, or the associated respiratory disease. These possibilities must be separated because they require different evaluations. Marked hypoxemia and tachypnea should not be attributed to simple pericarditis without considering pneumonia, pulmonary embolism, or heart failure. Exercise capacity may also remain reduced after control of the attack because of deconditioning, but progressive worsening or dyspnea at rest requires reassessment.

The pericardial friction rub may be transient and absent on many examinations, whereas ECG may show diffuse ST-segment elevation and PR depression. None of these findings has viral specificity. Physical examination should include vital signs, perfusion, venous pressure, pulmonary findings, and signs of systemic disease. Skin lesions, lymph nodes, hepatosplenomegaly, and mucosal manifestations may suggest a particular infection or an alternative diagnosis without replacing appropriate confirmation.

The pericardial effusion impairs filling when external pressure rises beyond the capacity for adaptation. The rate of accumulation is decisive: a rapidly progressive collection may be dangerous even without exceptional size. Tachycardia, hypotension, jugular venous distention, pulsus paradoxus, and signs of hypoperfusion require assessment for tamponade. A presumed viral origin does not change the hemodynamic priority and does not justify waiting for infectious testing before necessary drainage.

The myopericarditis denotes a clinical overlap in which myocardial injury must be characterized with troponin, ventricular function, and appropriate imaging. When myocardial dysfunction, arrhythmias, or instability predominate, risk cannot be equated with isolated pericarditis. Pain and biomarkers may resemble an acute coronary syndrome; the diagnostic pathway must consider age, risk factors, and the characteristics of the findings. Cardiac magnetic resonance helps characterize the lesion but does not identify the virus by itself.

In immunocompromised patients, the presentation may be less typical and more severe. An attenuated febrile response is not reassuring in the presence of hemodynamic deterioration or a significant collection. The course of an opportunistic infection may depend on viremia, involvement of other organs, and intensity of immunosuppression. In these cases, pericardial assessment is part of the systemic picture and bacterial, fungal, and neoplastic hypotheses must remain open. The viral label should result from reasoning rather than being an initial label that narrows it.

Investigations and degree of certainty of the viral diagnosis

The first objective is to document pericarditis with a coherent combination of clinical presentation and objective findings. Typical pain, friction rub, ECG changes, and a new or increased effusion are the traditional elements; inflammatory markers and tissue imaging add information in less evident cases. Syndromic diagnosis precedes etiologic attribution. A positive swab in a person with nonspecific pain does not replace demonstration of a pericardial process.

ECG, echocardiography, C-reactive protein, complete blood count, and troponin are generally central to evaluation. Renal function, electrolytes, and other tests are integrated according to context and therapeutic needs. Echocardiography defines the size and distribution of fluid, ventricular function, and hemodynamic consequences; pericarditis without effusion may still have an echocardiogram without specific abnormalities. Cardiac magnetic resonance is used to clarify pericardial or myocardial inflammation, particularly in uncertain cases or an unfavorable course.

Levels of evidence to distinguish in viral attribution

• Pericarditis with a preceding syndrome compatible with a viral illness, without identification of the agent: presumptive attribution.
• Documented viral infection in an extracardiac compartment with temporally associated pericarditis: a clinical association requiring interpretation.
• Viral detection in pericardial fluid or tissue with coherent clinical, histologic, and molecular data: stronger local evidence, to be assessed for causal relevance.
• Persistence or recurrence after resolution of the infection: possible postinfectious or immune-mediated phase, without automatic proof of replication.

This distinction represents an interpretive hierarchy, not a validated numerical classification. Routine viral serologies have little value for establishing a pericardial origin: antibodies may document past infections or a systemic response without cardiac localization. Contemporary recommendations discourage indiscriminate panels. Selective tests for infections such as HIV or hepatitis C may be appropriate when the context justifies them, but a positive result does not automatically attribute the effusion or inflammation to that virus.

The molecular diagnostics should answer a precise question. Respiratory positivity identifies the pathogen in the airways; viremia describes systemic circulation and may be useful in specific infections; a pericardial sample provides local information but may be influenced by blood contamination and infected circulating cells. For viruses capable of latency, presence of the genome and active replication are not synonymous. Quantification, comparison with blood, and tissue characteristics may aid interpretation in specialized centers without eliminating all uncertainty.

The invasive sampling is not justified in most mild forms solely to obtain the name of the virus. Pericardiocentesis or biopsy is considered when there is a therapeutic indication or a diagnostic question capable of changing management. Endomyocardial biopsy, when indicated for myocarditis, analyzes a different compartment and does not automatically replace pericardial characterization. Expected benefit must exceed procedural risk; retaining a diagnosis of presumed viral pericarditis may be more scientifically accurate than assigning certainty to a result of ambiguous significance.

Differential diagnosis and definition of disease after onset

The first differential diagnosis concerns thoracic emergencies. Acute coronary syndrome, pulmonary embolism, and aortic syndrome may present with pain and biomarker abnormalities, whereas pneumonia and pleuritis may accompany a viral illness without true pericardial involvement. Suspicion of a viral origin does not justify stopping these diagnostic pathways when the findings make them plausible. Distinction requires integrated assessment and, when indicated, specific coronary imaging or testing.

In comparison with other pericardial etiologies, persistent fever, a large effusion, subacute onset, and lack of response are reasons to broaden the investigation. Tuberculosis should be considered according to exposure and immune status; a purulent collection may emerge in the setting of thoracic or systemic infections. Malignancy, autoimmune disease, and iatrogenic injury may coincide temporally with a common respiratory infection. The latter should not become the preferred explanation when other elements have stronger causal weight.

Assessment of myocardial involvement includes troponin trend, ventricular function, ECG, and cardiac magnetic resonance in appropriate cases. Persistent palpitations, syncope, or documented arrhythmias require rhythm surveillance proportionate to risk. Indications for myocardial biopsy depend on severity and the possibility of identifying a histologic pattern or treatable cause; they do not arise automatically from a modest isolated increase in troponin. The final diagnosis should make clear whether risk is dominated by the pericardium, myocardium, or both.

In patients with documented systemic infection, further evaluation also considers other organs and immune conditions. The decision to treat a cytomegalovirus infection, for example, cannot be based solely on chest pain but requires assessment of disease in the context of transplantation or immunosuppression. In a patient with HIV, immune status and the possibility of opportunistic infections guide testing. Specialist coordination avoids both unnecessary antiviral therapy and failure to recognize systemic disease that requires treatment.

The reassessment of response occurs early, checking pain, temperature, drug tolerance, and inflammatory markers when initially elevated. The effusion is followed according to its size and risk without mechanically repeating every test in all cases. Reduced pain with increasing fluid or new dyspnea does not represent satisfactory remission. Conversely, a residual cardiac magnetic resonance finding in a clinically recovered patient should be interpreted over time rather than always equated with persistent infection.

Development of recurrences changes the clinical question. New activity should be documented and distinguished from residual pain, followed by assessment of whether there is evidence of a new infection or an immune-mediated response. Recurrences after a presumed viral trigger are often managed according to the pericardial phenotype without repeating viral panels at every attack. A substantial change in presentation, however, requires reconsideration of the cause and may make the previous attribution inadequate. Continuity of follow-up allows this difference to be recognized.

Anti-inflammatory therapy, antivirals, and management of physical activity

In uncomplicated presumed viral forms in immunocompetent patients, treatment is generally directed at pericardial inflammation. Aspirin or an NSAID is combined with colchicine when appropriate, with selection based on renal function, bleeding and gastrointestinal risk, comorbidities, and interactions. In adults, ibuprofen 600-800 mg every eight hours or aspirin 750-1,000 mg every eight hours are commonly used regimens during the active phase; tapering follows clinical response and activity markers. Doses and drug choice are not applicable indiscriminately to every age or clinical condition.

The colchicine is generally given at 0.5 mg once daily in patients weighing less than 70 kg and 0.5 mg twice daily at 70 kg or more, with necessary adjustments. In a first episode, treatment generally lasts at least three months and longer for recurrences according to the course. Evidence of efficacy derives from populations with acute or recurrent pericarditis, often idiopathic or presumed viral, not from trials dedicated to each agent. The benefit concerns control of the syndrome and prevention of recurrences, not viral eradication.

Safety requires attention to drug interactions, particularly in immunosuppression and during antiviral treatment. P-glycoprotein and CYP3A4 inhibitors can increase colchicine exposure, with greater risk in renal or hepatic impairment. Some ritonavir-containing regimens make specialist review of applicable combinations and contraindications particularly important. Significant diarrhea, muscle weakness, cytopenias, or organ abnormalities should not be attributed without evaluation to the infection alone. The prescription must consider the entire medication regimen.

The corticosteroids are not the usual first choice for an uncomplicated presumed viral episode. They may be necessary for specific indications or inability to use conventional options, after weighing infectious risk. A documented active viral infection requires caution with immunosuppression; a postinfectious phase or persistent immune phenotype raises different questions. The decision does not arise from the word viral alone but from the probability of replication, severity, and alternatives. When used for pericarditis, doses and tapering should avoid unnecessarily high exposure or rapid fluctuations.

The antivirals are not indicated empirically for every pericarditis preceded by a viral illness. There is no evidence supporting a universal antiviral strategy in isolated presumed viral pericarditis. Direct treatment may be appropriate when a treatable agent causes documented disease that requires it, especially in immunosuppression, according to infectious disease indications. Historical proposals involving interferons or immunoglobulins for specific infections should not be presented as a general standard. Treatment of influenza or COVID-19 likewise follows indications for the infectious disease and does not automatically constitute proven therapy for the pericardial lesion.

The immune-mediated persistence may require a pathway different from antiviral treatment. In patients with documented inflammatory recurrences and appropriate clinical criteria, interleukin-1-targeted therapies may be considered in specialist care. Evidence from recurrent forms does not demonstrate efficacy for replicative pericardial infection caused by any virus and does not remove the need to exclude relevant infections. Treatment of tamponade remains a priority and consists of drainage when indicated; no anti-inflammatory or antiviral drug replaces correction of hemodynamically significant compression.

The exercise restriction during inflammatory activity reduces exposure to cardiovascular stress while the disease is characterized and treated. Return to activity is individualized after clinical remission and assessment of relevant tests. In the presence of myocarditis, dysfunction, or arrhythmias, specific criteria and more extensive evaluation are required before intense sport. A negative swab is not sufficient to authorize return to activity: the end of contagiousness and cardiac recovery are distinct issues. A gradual pathway also allows recognition of new symptoms and recovery of conditioning.

Prognosis, complications, and follow-up

The prognosis of isolated presumed viral pericarditis in an immunocompetent person is generally favorable, particularly when there is no large effusion, hemodynamic compromise, or relevant myocardial injury. This statement concerns a selected clinical category and does not describe all cardiac viral infections. Severe systemic disease, opportunistic reactivation, or myocarditis with dysfunction may dominate the outcome. Risk description should therefore state which compartments are involved and which elements support the etiologic attribution.

The recurrences are an important source of morbidity. A subsequent episode may reflect immune activity rather than new acquisition of the same virus. It is therefore incorrect to interpret every flare as persistent contagiousness or failure of an eradication that was never demonstrated. Colchicine reduces risk in appropriate populations but does not guarantee permanent remission. Management requires documentation of the attack, review of previous therapy, and attention to the possibility of noninflammatory chest pain between episodes.

The tamponade is less frequent in idiopathic or presumed viral presentations than in some specific etiologies but remains a potentially urgent complication. The evolution of the fluid and its effects on filling matter more than the etiologic label alone. After drainage, persistently elevated venous pressures or constrictive Doppler signs require consideration of an effusive-constrictive phenotype, in addition to residual collections and right ventricular dysfunction. Removal of fluid resolves the compressive component but does not exclude temporary associated tissue restriction.

The chronic constriction is rare in correctly classified presumed viral forms. Its development should prompt reassessment of history, epidemiologic context, and alternative causes, in addition to distinguishing reversible inflammatory restriction from persistent fibrosis. Edema, ascites, and reduced exercise tolerance may be more evident than pain. Functional echocardiography and cardiac magnetic resonance help define physiology; thickened pericardium alone is not sufficient to prove that congestion is caused by constriction.

The myocardial follow-up becomes important when troponin is elevated, function is abnormal, or arrhythmias are present. Normalization of pericardial symptoms does not guarantee resolution of concomitant myocardial injury. Follow-up frequency and the need for rhythm monitoring depend on the initial findings and evolution. Syncope, sustained palpitations, or worsening dyspnea require renewed assessment. Return to sport should be based on overall cardiac recovery rather than only on cessation of infectious symptoms.

The prevention follows two distinct tracks. Recommended measures against viral infections reduce the risk of target diseases according to applicable indications, without guaranteeing absence of any pericarditis. Prevention of recurrences instead depends on control of inflammation, adherence, and appropriate tapering. Contagiousness is assessed according to the agent and phase of infection, not isolated persistence of pericardial pain. Explaining this distinction avoids unnecessary restrictions and helps the patient recognize which symptoms require cardiologic reassessment.

References
1. Schulz-Menger J et al. 2025 ESC Guidelines for the management of myocarditis and pericarditis. European Heart Journal. 2025;46(40):3952-4041.
2. Wang TKM et al. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on the Diagnosis and Management of Pericarditis: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2025;86(25):2691-2719.
3. Klein AL et al. Pericardial Diseases: International Position Statement on New Concepts and Advances in Multimodality Cardiac Imaging. JACC: Cardiovascular Imaging. 2024;17(8):937-988.
4. Adler Y et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases: The Task Force for the Diagnosis and Management of Pericardial Diseases of the European Society of Cardiology (ESC). Endorsed by: The European Association for Cardio-Thoracic Surgery (EACTS). European Heart Journal. 2015;36(42):2921-2964.
5. Mauro AG et al. The Role of NLRP3 Inflammasome in Pericarditis: Potential for Therapeutic Approaches. JACC: Basic to Translational Science. 2021;6(2):137-150.
6. Gluckman TJ et al. 2022 ACC Expert Consensus Decision Pathway on Cardiovascular Sequelae of COVID-19 in Adults: Myocarditis and Other Myocardial Involvement, Post-Acute Sequelae of SARS-CoV-2 Infection, and Return to Play: A Report of the American College of Cardiology Solution Set Oversight Committee. Journal of the American College of Cardiology. 2022;79(17):1717-1756.
7. Imazio M et al. Prevalence of C-reactive protein elevation and time course of normalization in acute pericarditis: implications for the diagnosis, therapy, and prognosis of pericarditis. Circulation. 2011;123(10):1092-1097.
8. Imazio M et al. A randomized trial of colchicine for acute pericarditis. New England Journal of Medicine. 2013;369(16):1522-1528.
9. Imazio M et al. Risk of constrictive pericarditis after acute pericarditis. Circulation. 2011;124(11):1270-1275.
10. Spodick DH. Acute cardiac tamponade. New England Journal of Medicine. 2003;349(7):684-690.
11. Brucato A et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. JAMA. 2016;316(18):1906-1912.
12. Klein AL et al. Phase 3 Trial of Interleukin-1 Trap Rilonacept in Recurrent Pericarditis. New England Journal of Medicine. 2021;384(1):31-41.
13. Imazio M et al. Indicators of poor prognosis of acute pericarditis. Circulation. 2007;115(21):2739-2744.
14. U.S. National Library of Medicine. COLCHICINE tablet, film coated: prescribing information. DailyMed. n.d. Accessed September 26, 2026. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=50b9c910-49a3-4a57-80f5-dc36c09da4df.